Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
Cancer patients are suffering serious health consequences because step therapy practices enforced by pharmacy benefit managers (PBMs) are preventing timely access to essential medicines, […]
Oncologist warns PBM step therapy has ‘crossed a dangerous line’ Read More »
European countries don’t just pull prices for medicines out of thin air. The prices that those governments set are based on specific sets of
It is often taken as a given that drug prices in the U.S. are higher than those in other nations. And while there is
Putting Americans First: International prices in context Read More »
The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the prices. They’re in the
“Small companies are the lifeblood of the industry and a lot of what they do, and what they’re experiencing, greatly affects the industry as
Emerging biotechs get bearish to weather market trends, finds BIO report Read More »
Even if they aren’t making revenue, small biotechs can face onerous reporting requirements that cost $1 million or more, cutting into the firms’ ability
Onerous reporting requirements crushing small biotechs, BIO Board member testifies Read More »
The rare disease patient community is the beating heart of the Biotechnology Innovation Organization’s (BIO) mission. Whether it is driving policy that supports innovation,
BIO 2025: Rare disease patients can’t wait Read More »
Day 1 of BIO 2025 was all about collaboration: how industry can collaborate with the U.S. government to advance biodefense, how collaboration is key
BIO 2025: A few highlights from Day 1 Read More »
The One Big Beautiful Bill Act – the “reconciliation bill” being considered by Congress – features policies that are crucial for driving American innovation.
Legislation introduced by Senators John Barrasso (R-WY) and Martin Heinrich (D-NM) would help protect the research and development of new treatments for patients with
Senators introduce bipartisan bill to protect new medicines for rare disease Read More »
